ADJUVANT THERAPY FOR HER-2 POSITIVE BREAST CANCER: EXPERIENCE IN THE

Leonardo Villacres Montesdeoca; Carol Albacura; Jessica Romero Mazon; Mayra Beltran Ortiz; Jose Hidalgo Olalla; Viviana Aguirre Carvajal; Diana Argoti Lima; Rene Munoz

Volume : VIII, Issue : V, May - 2019

ADJUVANT THERAPY FOR HER-2 POSITIVE BREAST CANCER: EXPERIENCE IN THE

Leonardo Villacres Montesdeoca, Carol Albacura, Jessica Romero Mazon, Mayra Beltran Ortiz, Jose Hidalgo Olalla, Viviana Aguirre Carvajal, Diana Argoti Lima, Rene Munoz

Abstract :

Objectives: to describe the demographic variables in adjuvant therapy for HER–2 positive east cancer, and to assess the response to trastuzumab compå with chemotherapy alone. Methods: A general descriptive analysis of women older than 18 years was carried out in whom therapy adjuvant was performed, assessing overall survival, survival estimation was performed by Kaplan Meier method and survival functions were compared using the Long Rank test. Results: Adjuvant therapy was performed in 68 patients in stage I (21 / 30.9%) II (28 / 41.2%) and III (19 / 27.9%), with a overall survival of 61 months in patients treated with trastuzumab alone or TCH scheme, 58.2 months for patients treated with chemotherapy, and 68.2 months for patients treated with chemotherapy followed by trastuzumab p = 0.16, in terms of immunophenotype HER–2 positive vs HER–2 (positive)/ RH (hormonal receptor) was 68.9 months vs. 62.6 months p = 0.21 Conclusion: Although the main weakness of this study is that it is a retrospective trial, it should be noted that there were stage I patients treated only with trastuzumab and perhaps the benefit of the trastuzumab–taxane association was lost, however it should be noted that in any of the scenarios there is a benefit in associating adjuvant therapy with tratuzumab to using chemotherapy alone.